[{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Virtus Respiratory Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Virtus Respiratory Research","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Virtus Respiratory Research"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Vaxart","sponsor":"Altesa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Altesa Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Altesa Biosciences"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vapendavir","moa":"VP1 capsid protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Altesa Biosciences \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Vapendavir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a broad-spectrum antiviral medicine that prevents the virus from entering human cells and reproducing. It is being studied for rhinovirus infections in people with COPD.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 19, 2025

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 19, 2025

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 29, 2023

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Virtus Respiratory Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 27, 2023

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : BTA798 (Vapendavir) has shown promising preclinical and clinical data demonstrating effective control of certain respiratory viruses, can potentially be used to treat epidemic hand, foot and mouth disease (HFMD) and HRV infection in COPD Patients.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Altesa is granted the worldwide, exclusive right to develop, manufacture, and commercialize Vaxart’s proprietary formulation of Vapendavir.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          July 07, 2021

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Altesa Biosciences

                          Deal Size : $130.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinovirus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 18, 2017

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Aviragen Therapeutics

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Aviragen Therapeutics

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 24, 2016

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Biota Pharmaceuticals

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Biota Pharmaceuticals

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 20, 2015

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Biota Pharmaceuticals

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Biota Pharmaceuticals

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Details : Vapendavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 02, 2014

                          Lead Product(s) : Vapendavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank